underway some initiatives have of will afternoon, cord third to in the On quarter line line reach good provide portfolio significant expand and tissue our you, consistent enhance and the top of top reported today's growth and key value. morning, growth double-digit Yesterday operations, we of and call, behind straight everyone. on products. our Jack, drivers our streamline highlight shareholder continuing I Thank update an we
net quarter grew this sales of First portfolio XX% year-over-year.
the resources Last improving executing We reorganized in year, performance. our the are focused to taking We and teams, and in sales strong on optimization execute to our marketing fundamentals driving ability we assist sales commercially. educational force strategy completely on enhanced of major sales force. a growth step our geographic
align we colleagues reward and revenue products. Additionally, short, the and highly economic trained communicate MiMedx professionals a sales compensation to have changes we are date we the plan our made growth. most the working. to In clinical sales to value of believe I market-leading have agency
traction expanding reach are procedures patients surgical are address better We and complex to gaining clinical seeking new a the are in where and outcome. where our under-penetrated cases recovery solutions looking market customers by for our
significant make teams our toward research to and the The of we over executing, continue targeted initiatives product double-digit as objective coming are fruition, are growth. sustainable implemented commercial, execute to year us toward progress Our collaborating development to and our we allowing objectives. past
EPIFIX continuing strong in major off closed The gap. essentially in following discretion, our enforcement came Following launch the With of our products reimbursement of approval XX% market. XXX performance end near-term portfolio, contributor the top of we is have for line Japan we the a shortfall quarter's this as Section the faced expected this product. that
gain XX been process since regarding in readiness complete Though plans. COVID decisions Japan launch of with in approval. for months focused on in time review reimbursement Japan, efforts regulatory companies remain we X to many our The to then, have the reminder, to As are approval regulatory last this has vigilant reimbursement Health approval. lines. we we and to our process the received will reimbursement reimbursement a And EPIFIX slowed dialogue marketed in for constant be down seeking June. In typically following Ministry takes meantime,
for gained distributor use, of have our the supplement to clinical well we all giving market marketing, as a infrastructure. putting on stand have supporting our to attractive reimbursement, MiMedx us. advantage. and in we evaluations to the ground Thanks to that very ready first-mover identified place key the shortly to part on local Japan opinion clinical direct product And societies. date. progress We our leaders efforts, of approved for our product and help We key a of in to go-to-market selected the first amniotic regulatory our to will strategy. are officially I thereafter. moment a is local necessary acknowledge way and initial confident instrumental only launch been to the This take have remain distributor their our teams, have Japan, prominent in would and like EPIFIX ability whom support product resources operations, sites the will be our medical a secure and we
is we in Japan estimate which US. and with here anticipate coverage hard-to-heal coverage our include broader access all the addressable regulatory we operations Japan We just product. patients, market XXX,XXX our for can clinical total approximately of groups to Our patients labeling the negotiated considerably and over XXX,XXX than in the is for that those in wounds, EPIFIX
or collagen the our of PCM. matrix now U.S., our Turning planned to new products the two in launch AMNIOEFFECT product and placental
these innovative this are of about to half We year. back expect the product launch we in which of introductions, both bullish
to AMNIOEFFECT direct have in can market that teams This wound a need. thicker AmnioFix, where been hold product suture procedures portfolio but AMNIOEFFECT. offering, a our At believe experience sales a surgical the repair needs AMNIOCORD EPIFIX larger can or as is First, suture. target with anchor launch, will for complex is address rotator a agency and asking our to and surgeon similar membrane a graft such size Customers a cuff or we and reconstruction. and using
than release for market the for month XX track on evaluations. more identified have next and limited clinical first sites are a unique We
We introduction, product that be disc deep and primarily that panels made features PCM and target will dHACM positive an injectable the in particulate accelerate in product from to market trial wounds reach biologics meaningful OA Transitioning planned product clinical available to and steps for shared for provided second outstanding We our and and representatives in a we this our platform about complex liaisons products. PCM the or the be use sales are benefits. excitement ready difficult enrollment will know Advisory Our our tunneling format ready medical are conventional is our its view to opportunity, placental micronized engage with start as program. of is trial to launch. late-stage customers drug Knee evaluated pipeline. feedback when and those the to taking novel
Our experts clinical up resources for the Bob consistent in along scientific our preparing the of the osteoarthritis. with under of studies efforts, industry-leading team operations to our knee we the leadership in And Stein clinical industry initiation world-class of osteoarthritis. next are lining Dr. with own and augment field practices, is best
sports on monitoring, are analysis assessing rigorously in Furthermore, Advisory to with on site pipeline company's near OA, on third-party studies data Knee we exceptional our our been micronized and providing look the in reporting statistical drive both an as can engaged help that high-level micronized towards These activities, medicine. us trial well management, future. and oversee way to very enthusiasm dHACM and dHACM injectable formation have progress in and Scientific to collaborators counsel injectable help I'm clinical updating share external share forward. and I eager in of expert with forward about We the placental perspective and charged the other biologic individuals indications who and are excited Board, disease well clinical as be you MiMedx' musculoskeletal to registrational our
addition, approved, In working the market R&D see suffering a study underlying for safe patients imperative path to IIb on diseases fast underlying on these asked on be research our from and dHACM our where strategy. we from If teams disease suffering generation options action the our I've we treatment further initiatives is programs, and of from build knee derived KOA process. accelerate our effective impact revenue track data mechanism these the to are in and blockbuster can serving patients potential educate these and void we other It the gaping potential to publication in accelerate of our beneficial. to osteoarthritis clinically micronized Phase
Now turning within units the defined April, strategic to we cohesive two internal created company. business initiatives. In
that is growing two product And first our our development Care portfolio focused launch Surgical business. and and The on existing each charged team part year. and is markets, new important of an is products recovery with existing near-term innovation. This of the Wound
significantly on our improving focused index. overall vitality are product We
R&D The the strategic company. accomplish The progressing most have growth double-digit business platform osteoarthritis. that our organizational MiMedx. each business the at well necessary our I'm team our achievements technologies, unit business next to The our innovate, that create consistently unit positions drive assembled areas for commercial at patients And where realignment growing second in value experienced specifically in outlined. they we leadership Moreover, innovation performing are for talented, on can programs. an and for structure senior these as collective abilities our equipped knee to medicine and is milestone to of initiatives is placental MiMedx achieve to on provides focused for towards and your this in best treatment focus shareholders. rates. allows biologics have times These confident and we it the biological This is funds the FDA-approved drug registration regenerative for execute exciting phase research
to call our review a like results. first I'd to over Now quarter of Pete? the Pete turn for
